Pfizer launches phase III trial with RSV candidate in September

Following positive data from a phase IIa trial, Pfizer is ready to launch a phase III trial with adults next month with the vaccine candidate rsvpref for treating respiratory syncytial virus (RSV).

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Following positive data from a phase IIa trial, US pharmaceutical company Pfizer is ready to initiate another phase III trial with the vaccine candidate RSVpreF fo treating respiratory syncytial virus (RSV), according to Fiercebiotech.

The media points towards the pharmaceutical company's Q2 report, which was published last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Further reading

Related articles

Latest news

See all jobs